Farmas USA

Carai.. por ahora se portan muy bien... :O

CLDX

CLDX

Joer, y tan bien, si las vendes ahora, les sacas un +5%, pero yo las aguantaría a ver.

De momento, verde, pero veremos si aguanta....
Con los palos que llevamos últimamente, ya tocaría un día de super rebotón.....
En cabeza en cartera, las CTIX, +4,4%, que fueron las únicas que ayer cerraron en verde, por la new que sacaron, según la cual,, elegían cardos directivos independientes...
Se ve que para acceder al NASDAQ, tienes que tener directivos independientes o algo así....
Todo parece indicar que siguen en el camino correcto para el uplist....

Cellceutix Selects Independent Directors and Committee Members

ECCMID Presentations Available on Cellceutix Website Today

BEVERLY, MA--(Marketwired - Apr 27, 2015) - Cellceutix Corporation (OTC: CTIX) (the "Company"), a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, and antimicrobial applications, is pleased to announce the selection of Dr. Barry Alan Schechter, Dr. Zorik Spektor and Mark Tobin as qualified independent directors and committee members of the Company's Board of Directors.

Barry Schechter, M.D., F.A.A.O. - Dr. Schechter, age 51, is the Director of Department of Cornea and External Disease at Florida Eye Microsurgical Institute from the year 2005 to the present. He was co-founder and the original CEO of Pediavision, a company that was dedicated to saving children's eyesight; the company and its innovative technology was recently sold. He is an expert consultant for Gerson Lehrman Group regarding the business and technology of eye care. Dr. Schechter's practice involves diseases of the ocular surface, including dry eyes, allergies, infection, the latest in corneal, refractive and cataract surgery, and glaucoma. He is on the Editorial board for Advanced Ocular Care, a journal that reaches the top 10% of ophthalmologists and select optometrists. Dr. Schechter has reviewed articles for Cornea, the British Journal of Ophthalmology, and Journal of the American Academy of Ophthalmology. He has lectured internationally and published about treatment of ocular tumors, on lens implants, on dry eyes, and written a textbook chapter on surgical techniques. Dr. Schechter is involved in clinical research and consults for several ophthalmic pharmaceutical companies.

Zorik Spektor, M.D., F.A.A.P. - Dr. Spektor, age 58, is a fellowship trained Pediatric Otolaryngologist and Head and Neck Surgeon. He is Director of The Center for Pediatric ENT - Head and Neck Surgery in Boynton Beach, Florida from the year 1995 to the present. In addition, he is a Voluntary Assistant Professor of Surgery at the Department of Otolaryngology, University of Miami Leonard M. Miller School of Medicine. He is also an Affiliate Clinical Assistant Professor of Biomedical Science at Florida Atlantic University in Boca Raton, Florida.

He received his Bachelor's Degree from Cornell University, and his Medical Doctorate at Albany Medical College of Union University in Albany, New York. He did his residency training in Otolaryngology - Head and Neck Surgery at the University of Connecticut and completed his fellowship in Pediatric Otolaryngology - Head and Neck Surgery at LeBonheur Children's Medical Center in Memphis, Tennessee. Dr. Spektor is board certified in Otolaryngology - Head and Neck Surgery. He is a Fellow of the American Academy of Otolaryngology - Head and Neck Surgery and American Academy of Pediatrics. He is also a member of the American Society of Pediatric Otolaryngology and Society for Ear, Nose & Throat Advances in Children.

Prior to establishing the Center for Pediatric ENT - Head and Neck Surgery in 1995, Dr. Spektor was on the faculty of the University of Connecticut Health Science Center, Hartford Hospital and Newington Children's Hospital, now known as Connecticut Children's Hospital. He has lectured and presented extensively in the field of pediatric otolaryngology and has numerous peer-reviewed publications. Dr. Spektor has been a presenter as well as an invited speaker at local, national and international conferences. He continually conducts clinical research studies, which have produced significant advances in the field of Pediatric Otolaryngology. During the past decade he has been selected as one of the nation's top doctors by several independent rating agencies for many consecutive years. Dr. Spektor has served on advisory boards for several medical device and pharmaceutical companies and has been involved in significant advances in the field of otolaryngology and Pediatric Otolaryngology.

Mark R. Tobin, MBA. - Mark Tobin, age 41, is Director of Research at Digital Offering, a merchant bank, from October 2013 to the present. In addition, he is a Managing Partner at Tobin Tao & Company, a market research and advisory firm from February 2013 to the present. Previously, from May 2005 to February 2013, Mr. Tobin served as Director of Research and as a Senior Research Analyst at Roth Capital Partners, where he oversaw equity research on hundreds of small-cap public companies across a variety of sectors. Prior to that, he was a Program Manager and Senior Systems Engineer at Science Applications International Corporation, a FORTUNE 500® scientific, engineering, and technology applications company. Mr. Tobin began his career as an officer in the United States Air Force, overseeing advanced technology development programs and representing the U.S. as a NATO delegate. He graduated with honors from the U.S. Air Force Academy with a Bachelor's of Science in Management and received an MBA from the University of Pittsburgh.

CTIX

Creo que estas hay que aguantarlas. Ayer cayeron demasiado, claramente porque alguien se puso nervioso al confundir el ticker e inicio una ola de ventas de pánico, y si tenemos en cuenta que su tendencia de base es alcista, al menos así lo veo, no creo que haya demasiado "peligro" por estar dentro un par de días.

CLDX

CLDN

+7%, ay madre, a ver si se fuera hoy a por los 5 dólares. Le costaría tan poquito, sólo una rayita de lo que bajó ayer, y me haría un gran favor, jejeje.

Carai... las tuyas si que rebotan... 7,20%... y subiendo. Muy bien. 

CLDN

CLDN

Han pasado ya los primeros minutos locos de la apertura, y no se ve pánico vendedor, a ver si siguen encarrilás así toda la sesión.

En las mias se ha acabado el pánico comprador... maldita sea... :D

CLDX